SAN DIEGO, CA--(Marketwired - Feb 4, 2016) - Cue, Inc. today announced a collaboration with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, (Janssen) to address a significant global health need for HIV viral load testing using Cue’s Lab-In-A-Box proprietary molecular diagnostics platform. The deal was facilitated by Johnson & Johnson Innovation.
Today, access to HIV viral load testing in resource poor settings is limited due to cost, and the technical complexity of the instrumentation and infrastructure required. An affordable, portable, easy-to-use, and internet enabled HIV quantitative viral load test could significantly enhance access to clinically significant information.
Patients with newly emerging viral load who remain on failing regimens run the risk of both disease progression and developing resistance to future treatment options. Hence, HIV viral load testing is key to optimal disease management in people living with HIV.
The scale of the HIV epidemic in Africa, India, Southeast Asia, and other parts of the developing world make this a significant global health challenge to be solved through strategic coordination between diagnostics, therapy, and on-the-ground deployment.
“We’re excited to work with Janssen, a leader in the HIV field, to accelerate the development of the HIV quantitative viral load test on Cue’s platform. Together we can make a big impact on this significant global health challenge by bringing simplicity, immediacy and affordability to the field of HIV viral load testing in an unprecedented way,” says Cue CEO Ayub Khattak.
About Cue
Cue Inc. is developing a molecular diagnostics platform for portable, connected, easy-to-use detection and quantification of molecular targets with applications to consumer health and fitness, longitudinal monitoring of biomarkers for chronic disease management, and infectious disease detection in support of global health initiatives.
